Download PDF
Thromb Haemost 1999; 81(02): 193-197
DOI: 10.1055/s-0037-1614441
Review Articles
Schattauer GmbH

The Factor V Gene A4070G Mutation and the Risk of Venous Thrombosis

Martine Alhenc-Gelas
1   From Laboratoire d'Hémostase, Service de Médecine Vasculaire, Centre Claude Bernard de Recherche sur les Maladies Vasculaires, Unité INSERM 428 and Unité INSERM 258, Hôpital Broussais – AP-HP, Paris, France, and Société Serbio, Gennevilliers, France
,
Viviane Nicaud
1   From Laboratoire d'Hémostase, Service de Médecine Vasculaire, Centre Claude Bernard de Recherche sur les Maladies Vasculaires, Unité INSERM 428 and Unité INSERM 258, Hôpital Broussais – AP-HP, Paris, France, and Société Serbio, Gennevilliers, France
,
Sophie Gandrille
1   From Laboratoire d'Hémostase, Service de Médecine Vasculaire, Centre Claude Bernard de Recherche sur les Maladies Vasculaires, Unité INSERM 428 and Unité INSERM 258, Hôpital Broussais – AP-HP, Paris, France, and Société Serbio, Gennevilliers, France
,
Patrick van Dreden
1   From Laboratoire d'Hémostase, Service de Médecine Vasculaire, Centre Claude Bernard de Recherche sur les Maladies Vasculaires, Unité INSERM 428 and Unité INSERM 258, Hôpital Broussais – AP-HP, Paris, France, and Société Serbio, Gennevilliers, France
,
Jean Amiral
1   From Laboratoire d'Hémostase, Service de Médecine Vasculaire, Centre Claude Bernard de Recherche sur les Maladies Vasculaires, Unité INSERM 428 and Unité INSERM 258, Hôpital Broussais – AP-HP, Paris, France, and Société Serbio, Gennevilliers, France
,
Marie-Laurence Aubry
1   From Laboratoire d'Hémostase, Service de Médecine Vasculaire, Centre Claude Bernard de Recherche sur les Maladies Vasculaires, Unité INSERM 428 and Unité INSERM 258, Hôpital Broussais – AP-HP, Paris, France, and Société Serbio, Gennevilliers, France
,
Jean-Noël Fiessinger
1   From Laboratoire d'Hémostase, Service de Médecine Vasculaire, Centre Claude Bernard de Recherche sur les Maladies Vasculaires, Unité INSERM 428 and Unité INSERM 258, Hôpital Broussais – AP-HP, Paris, France, and Société Serbio, Gennevilliers, France
,
Joseph Emmerich
1   From Laboratoire d'Hémostase, Service de Médecine Vasculaire, Centre Claude Bernard de Recherche sur les Maladies Vasculaires, Unité INSERM 428 and Unité INSERM 258, Hôpital Broussais – AP-HP, Paris, France, and Société Serbio, Gennevilliers, France
,
Martine Aiach
1   From Laboratoire d'Hémostase, Service de Médecine Vasculaire, Centre Claude Bernard de Recherche sur les Maladies Vasculaires, Unité INSERM 428 and Unité INSERM 258, Hôpital Broussais – AP-HP, Paris, France, and Société Serbio, Gennevilliers, France
› Author AffiliationsThis work was supported by a grant from Programme Hospitalier de Recherche Clinique no. AO94031 “Evaluation clinique et biologique de risque thrombotique”.
Further Information

Publication History

Received07 August 1998

Accepted after resubmission27 October 1998

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

Summary

The A4070G polymorphism in exon 13 of the factor V (FV) gene, which replaces His by Arg at position 1299 of the B domain, was recently shown to influence circulating FV levels and to contribute to the activated protein C (APC) resistance phenotype. We examined the impact of this polymorphism in a population of unselected patients with venous thromboembolic disease (VTE). The prevalence of the G4070 (R2) allele was determined in 205 patients and 394 healthy subjects of similar age and sex distribution. Thirty-seven patients (18%) were heterozygous for the R2 allele and 1 (0.5%) was homozygous. Forty-four controls (11.2%) were heterozygous for the R2 allele and 1 (0.2%) was homozygous. Thus, the allelic frequency was significantly higher in the patients with VTE than in the healthy controls, with respective values of 9.5% and 5.8%. The odds ratio was 1.8 (95% CI: 1.1-2.8, p = 0.02), pointing to an increased risk of VTE in carriers of the R2 allele. After excluding subjects with putative or confirmed gene defects (mainly the FV R506Q mutation), the R2 allele was still a risk factor for VTE in the remaining patients, with an odds ratio of 2.0 (95% CI: 1.2-3.5, p = 0.01), demonstrating that this polymorphism is itself a risk factor. This study also confirms that the R2 allele influences APC resistance (APCR) in the absence of the FV R506Q mutation.

 

  • References

  • 1 Hoyer LW, Wyshock EG, Colman RW. Coagulation cofactors: factors V and VIII. Colman RW, Hirsh J, Marder VJ, Salzman JB EW. eds Philadelphia: Lippincott Company; 1994: 109-33.
    Google Scholar
  • 2 Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in the FV R506Q. J Biol Chem 1995; 270: 4053-7.
    CrossrefPubMedGoogle Scholar
  • 3 Shen L, Dahlbäck B. Factor V and protein S as synergic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735-8.
    PubMedGoogle Scholar
  • 4 Lu D, Kalafatis M, Mann KG, Long GL. Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V. Blood 1996; 87: 4708-17.
    PubMedGoogle Scholar
  • 5 Varadi K, Rosing J, Tans G, Pabinger I, Keil B, Schwarz HP. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor V R506Q mutation. Thromb Haemost 1996; 76: 208-14.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Thorelli E, Kaufman RJ, Dahlbäck B. The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V. J Biol Chem 1998; 273: 16140-5.
    CrossrefPubMedGoogle Scholar
  • 7 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by a poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
    CrossrefPubMedGoogle Scholar
  • 8 Dahlbäck B. Resistance to activated protein C caused by the factor V R506Q mutation is a common risk factor for venous thrombosis. Thromb Haemost 1997; 78: 483-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-6.
    CrossrefPubMedGoogle Scholar
  • 10 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
    CrossrefPubMedGoogle Scholar
  • 11 Aparicio C, Dahlbäck B. Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506Gln mutation in the factor V gene. Biochem J 1996; 313: 467-72.
    CrossrefPubMedGoogle Scholar
  • 12 Roelse JC, Koopman MMW, Büller HR, ten Cate JW, Montaruli B, van Mourik JA, Voorberg J. Absence of mutations at the activated protein C cleavage sites of factor VIII in 125 patients with venous thrombosis. Brit J Haematol 1996; 92: 740-3.
    CrossrefPubMedGoogle Scholar
  • 13 Bokarewa I M, Falk G, Bremme K, Blomback M, Wiman B. Search for mutations in the genes for coagulation factors V and VIII with a possible predisposition to activated protein C resistance. Eur J Clin Invest 1997; 27: 340-5.
    CrossrefPubMedGoogle Scholar
  • 14 Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg 306 of factor V gene in Hong Kong Chinese. Blood 1998; 91: 1135-9.
    PubMedGoogle Scholar
  • 15 Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306 to Thr) associated with resistance to activated protein C. Blood 1998; 91: 1140-4.
    PubMedGoogle Scholar
  • 16 Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. Biochemistry 1992; 31: 3777-85.
    CrossrefPubMedGoogle Scholar
  • 17 Lunghi B, Iacovello L, Gemmati D, Dilasio MG, Castoldi E, Pinotti M, Castaman G, Redaelli R, Mariani G, Marchetti G, Bernardi F. Detection of new polymorphic markers in the factor V gene: association with factor V levels in plasma. Thromb Haemost 1996; 75: 45-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Bernardi F, Faioni EM, Castoldi E, Lunghi B, Sacchi E, Mannucci PM. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997; 90: 1552-7.
    PubMedGoogle Scholar
  • 19 Working group on haemostasis of the Société Française de Biologie Clinique. Comparison of a standardized procedure with current laboratory practices for the detection of lupus anticoagulant in France. Thromb Haemost 1993; 70: 781-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Van Dreden P, Thuillier N, Amiral J, Bouyé M, Martinoli JL. Development and evaluation of a new activated protein C resistance assay: Staclot APC-R. Thromb Haemost 1997; 78: 20 (abstr).
    PubMedGoogle Scholar
  • 21 Vasse M, Van Dreden P, Thuillier N, Bouyé M, Vannier JP. A new chronometric assay based on the Va-dependent procoagulant activity of a snake venom for the detection of factor V Leiden. Thromb Haemost 1997; 78: 21 (abstr).
    PubMedGoogle Scholar
  • 22 Gandrille S, Alhenc-Gelas M, Aiach M. A rapid screening method for the factor V Arg 506 Gln mutation. Blood Coag Fibrinol 1995; 6: 245-9.
    CrossrefPubMedGoogle Scholar
  • 23 Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-50.
    PubMedGoogle Scholar
  • 24 Simioni P, Scarano L, Gavasso S, Sardella C, Girolami B, Scudeller A, Girolami A. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. Br J Haematol 1996; 92: 435-41.
    CrossrefPubMedGoogle Scholar
  • 25 Zoller B, Holm J, Svensson P, Dahlbäck B. Elevated levels of prothrombin activation fragment 1+2 in plasma from patients with heterozygous Arg 506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Thromb Haemost 1996; 75: 270-4.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Martinelli I, Bottasso B, Duca F, Faioni E, Mannucci PM. Heightened thrombin generation in individuals with resistance to activated protein C. Thromb Haemost 1996; 75: 703-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Bertina RM. Laboratory diagnosis of resistance to activated protein C (APC-resistance). Thromb Haemost 1997; 78: 478-82.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation of the 3' untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
    PubMedGoogle Scholar
  • 29 Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3' untranslated region of the prothrombin gene. Brit J Haematol 1997; 98: 907-9.
    CrossrefPubMedGoogle Scholar
  • 30 Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CRM. The prothrombin gene G20210A variant: prevalence in a UK anticoagulant clinic population. Brit J Haematol 1997; 98: 353-5.
    CrossrefPubMedGoogle Scholar
  • 31 Hillarp A, Zöller B, Svensson PJ, Dahlbäck B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost 1997; 78: 990-2.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Leroyer C, Mercier B, Oger E, Chenu E, Abgrall JF, Ferec C, Mottier D. Prevalence of 20210A allele of the prothrombin gene in venous thromboembolism patients. Thromb Haemost 1998; 80: 49-51.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Oger E., Leroyer C, Mercier B, van Dreden P, Bressollette L, de Saint-Martin L, Le Moigne E, Blouch MT, Thuillier N, Amiral J, Ferec C, Abgrall JF, Mottier D. Assessment of activated protein C resistance using a new and rapid venom-base test: STA Staclot APC-R. Blood Coag Fibrinol 1998; 9: 355-9.
    CrossrefPubMedGoogle Scholar
  • 34 Laffan MA, Manning R. The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul Fibrinol 1996; 7: 761-5.
    CrossrefPubMedGoogle Scholar
  • 35 Henkens CMA, Bom VJJ, van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII clotting activity. Thromb Haemost 1995; 74: 1606-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposition to thrombosis. Cell 1993; 72: 477-80.
    CrossrefPubMedGoogle Scholar
  • 37 Seligsohn U, Zivelin A. Thrombophilia as a multigenic disorder. Thromb Haemost 1997; 78: 297-301.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Koeleman BPC, Reitsma PH, Allaart RC, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-5.
    PubMedGoogle Scholar
  • 39 Zöller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-23.
    PubMedGoogle Scholar
  • 40 Gandrille S, Greengard JS, Alhenc-Gelas M, Juhan-Vague I, Abgrall JF, Jude B, Griffin JH, Aiach M. Incidence of activated protein C resistance caused by the Arg 506 Gln mutation in factor V in 113 unrelated symptomatic protein C deficient patients. Blood 1995; 86: 219-24.
    PubMedGoogle Scholar
  • 41 Zoller B, Svensson PJ, Dahlback B, Hillarp A. The A20210 allele of the prothrombin gene is frequently associated with the factor V Arg506 to Gln mutation but not with protein S deficiency in thrombophilic families. Blood 1998; 91: 2210-1.
    PubMedGoogle Scholar